Form 4: Karyopharm EVP Poulton Awarded 39,682 RSUs
Insider Transaction
Karyopharm Therapeutics Inc.'s EVP and Chief Development Officer, Stuart Poulton, was awarded 39,682 restricted stock units vesting in December 2026.
Summary
- Stuart Poulton, Executive Vice President and Chief Development Officer of Karyopharm Therapeutics Inc. (KPTI), was awarded 39,682 restricted stock units (RSUs).
- The transaction date for this award was October 15, 2025.
- The RSUs were granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
- These RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- The RSUs will vest 100% on December 31, 2026.
- Following this transaction, Stuart Poulton beneficially owns 67,392 shares of common stock directly.
Sentiment
Score: 7
Explanation: The RSU award is a positive event, indicating executive retention and alignment with shareholder interests, which generally contributes to stable management and long-term strategic focus. It is a routine compensation event, not a major operational or financial announcement.
Positives
- The award of restricted stock units aligns the interests of a key executive, Stuart Poulton, with those of shareholders, incentivizing long-term performance.
- The grant is part of an existing equity incentive plan, indicating a structured approach to executive compensation and retention.
Future Outlook
The awarded restricted stock units are scheduled to vest 100% on December 31, 2026, indicating a future milestone for the executive's equity compensation.
Industry Context
The award of restricted stock units to a key executive is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and motivate talent by aligning their long-term financial interests with company performance and shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | The award of RSUs was made pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, demonstrating the ongoing use of the company's established compensation framework. | 10/15/2025 | Reinforces the company's commitment to performance-based compensation and executive retention through its approved governance structures. |
Stakeholder Impact
- Shareholders: The RSU award aligns the interests of a key executive with shareholders, potentially fostering long-term value creation.
- Employees (Executive): Stuart Poulton's compensation package is enhanced, providing an incentive for continued service and performance.
Next Steps
- The restricted stock units will vest 100% on December 31, 2026, at which point they will convert into common stock.
Key Dates
| Date | Description |
|---|---|
| 10/15/2025 | Date of RSU award transaction for Stuart Poulton. |
| 10/16/2025 | Date the Form 4 was signed by Nancy Smith as Attorney-in-Fact for Stuart Poulton. |
| 12/31/2026 | Vesting date for 100% of the awarded restricted stock units. |
Keywords
Karyopharm Therapeutics, KPTI, Stuart Poulton, Restricted Stock Units, RSU award, Executive Compensation, Insider Transaction, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.